Navigation Links
VEGF Trap-Eye Submitted for EU Marketing Authorization for Treatment of Wet Age-Related Macular Degeneration
Date:6/7/2011

TARRYTOWN, N.Y. and BERLIN, June 7, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced that Bayer HealthCare has submitted an application for marketing authorization in Europe for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD). Regeneron and Bayer HealthCare are collaborating on the global development of VEGF Trap-Eye for the treatment of wet AMD, central retinal vein occlusion (CRVO), diabetic macular edema (DME), and myopic choroidal neovascularization (mCNV).

"The submission of VEGF Trap-Eye for EU marketing authorization represents a significant milestone in our goal to bring this potentially important new therapy to patients with wet AMD across the globe," said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron.

The VEGF Trap-Eye submission is based on the positive results from two Phase 3 trials, the VIEW 1 study and the VIEW 2 study.  In these trials, all regimens of VEGF Trap-Eye, including 2 mg VEGF Trap-Eye dosed every two months (following three loading doses), successfully met the primary endpoint of non-inferiority, compared to the current standard of care, ranibizumab 0.5 mg dosed every month.  The primary endpoint analysis was statistical non-inferiority in the proportion of patients who maintained (or improved) vision over 52 weeks compared to ranibizumab at the dose that is currently known to provide the best possible efficacy.  A generally favorable safety profile was observed for both VEGF Trap-Eye and ranibizumab.  The ocular adverse events were balanced across all treatment groups in both studies.  There were no notable differences in non-ocular adverse events among the study arms.

Regeneron submitted a Biologics License Application (BLA) for marketing approval in wet
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDA Schedules Advisory Committee Meeting to Discuss BLA for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration
2. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion
3. FDA Grants Priority Review for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration
4. Regeneron Submits Biologics License Application to FDA for VEGF Trap-Eye for Treatment of Wet Age-Related Macular Degeneration
5. Regeneron to Webcast Investor Briefing on VEGF Trap-Eye Clinical Program on Sunday, February 13th at 9 am ET
6. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME)
7. Regeneron Schedules December 20, 2010 Teleconference and Webcast to Discuss Results of VEGF Trap-Eye Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and Phase 2 Study in Diabetic Macular Edema (DME)
8. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
9. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
10. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
11. Vemurafenib New Drug Application Submitted to FDA for Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Mich. , Sept. 18, 2014  A $3 ... will allow the University of Michigan to establish a ... The Glenn Center for Aging Research at U-M ... that drugs can slow the effects of aging and ... mechanisms of aging that can help develop medications that ...
(Date:9/18/2014)... --  3D Systems   (NYSE: DDD ) announced ... a new robotic surgery skills and procedural training simulator, which ... exhibition in Amsterdam, The Netherlands from ... invasive surgery represents a growing portion of overall surgical volume, ... robotic surgery has increased, and it is expected that this ...
(Date:9/18/2014)... , Sept. 18, 2014  Halozyme Therapeutics, Inc. ... the U.S. Food and Drug Administration (FDA) has ... dosing of PEGPH20 in SWOG,s ongoing Phase 1b/2 ... evaluate Halozyme,s investigational drug PEGPH20 (PEGylated Recombinant Human ... in patients with metastatic pancreatic adenocarcinoma.  The study ...
Breaking Medicine Technology:$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 2$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 33D Systems Introduces New Simbionix Robotics Training Platform 23D Systems Introduces New Simbionix Robotics Training Platform 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 2SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 4
... Surgical, recently named one of Philadelphia,s 100 Fastest ... the healthcare marketplace with the acquisition of the ... surgical facilities to Millennium Surgical,s resources.  Its acquisition ... company has been undertaking for several years.  Millennium ...
... March 23, 2011 Polar ( ... assessment technology, today announced a partnership with celebrity fitness trainer ... president and CEO of NGR™ / No Gym Required™ ... a new show on the CW network, as a spokesperson ...
Cached Medicine Technology:Millennium Surgical adds "SurgicalInstruments.com" Name 2Polar Partners with 'Shedding for the Wedding' Trainer and NGR™ President and CEO Jennifer Cohen 2Polar Partners with 'Shedding for the Wedding' Trainer and NGR™ President and CEO Jennifer Cohen 3
(Date:9/18/2014)... NJ (PRWEB) September 18, 2014 ... firm, announced today that President and co-founder John ... Journal’s Innovation Award Winners for 2014, recognizing the ... him as an emerging executive of the year. ... care and life sciences that continue to shape ...
(Date:9/18/2014)... Qualis Health, one of the nation’s leading ... paper, “Advancing Primary Care through the Patient-Centered Medical Home ... Authors Jeff Hummel, MD, MPH and Peggy C. Evans, ... in the work of becoming a Patient-Centered Medical Home ... objectives, such as generating and providing useful data that ...
(Date:9/18/2014)... Baltimore, MD (PRWEB) September 18, 2014 ... Award-winning celebrity and wellness advocate, and Frank Davis, ... Activz Whole-food Nutrition, are pleased to announce ... 150+ ways to make delicious, nutrition-packed meals using ... book is the next step in the ...
(Date:9/18/2014)... of international scientists have developed a new method to ... . , The Wildlife Conservation Society (WCS)-led research, published ... , describes the use of fecal samples from wild ... exposed to the virus. This represents a new tool ... change the way Ebola virus is studied and improve ...
(Date:9/18/2014)... expect to pay higher employee contributions for their health ... officers about the impact of the Patient Protection and ... conducted by the Darla Moore School of Business at ... Patrick Wright, a professor in strategic human resource management, ... Officers. The survey is distributed to more than 560 ...
Breaking Medicine News(10 mins):Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2Health News:Advancing Primary Care Through PCMH and HIT: New White Paper Connects the Dots 2Health News:Montel Williams and Frank Davis Announce New Whole-Food Nutrition Recipe Book, The Simple Scoop, at Natural Products Expo East In Baltimore 2Health News:Montel Williams and Frank Davis Announce New Whole-Food Nutrition Recipe Book, The Simple Scoop, at Natural Products Expo East In Baltimore 3Health News:Research yields a game changer for improving understanding of Ebola and great apes 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 3Health News:Survey: Fortune 500 employees can expect to pay more for health insurance 2Health News:Survey: Fortune 500 employees can expect to pay more for health insurance 3
... regional networks , , FRIDAY, April 24 (HealthDay News) ... laboratory personnel has led to steady improvements in the ... a severe heart attack, new research shows. , The ... ST elevation myocardial infarction (STEMI), the deadliest type of ...
... Though soldiers tend to be healthier, trauma erases the advantage, ... Those serving in the armed forces tend to be in ... experienced combat duty, that initial health advantage is erased. , ... life than do non-combat veterans, according to a study that ...
... N.C. (April 23, 2009) Talecris Biotherapeutics, Inc. ... of life results from the largest clinical trial ... polyneuropathy (CIDP) in the April 14, 2009 issue ... that long-term treatment with Gamunex (Immune Globulin Intravenous ...
... ANGELES , April 24 MMR Information ... its wholly-owned operating subsidiary, MyMedicalRecords, Inc. (collectively, "MMR") ... www.mymedicalrecords.com ) and electronic safe deposit box ... a Webinar on the company,s products for healthcare ...
... ABC,s hit television show Grey,s Anatomy has selected the ... its favorite charities and has listed the AAN Foundation on the Grey,s ... and Dr. Derek "McDreamy" Shepherd. Fans and the public are encouraged ... lieu of gifts. The public can buy a virtual brain for ...
... "Pregnant women need our assistance now so that abortion ... April 24 Cardinal Rigali, chair of the Committee ... Bishops (USCCB), wrote to all U.S. Representatives urging them ... 2035) re-introduced in the House by Rep. Lincoln Davis ...
Cached Medicine News:Health News:Coordination Has Led to Quicker Heart Treatment 2Health News:Combat Duty Harms Long-Term Health of Vets 2Health News:Combat Duty Harms Long-Term Health of Vets 3Health News:Landmark study demonstrates Gamunex improves health-related quality of life in patients with CIDP 2Health News:Landmark study demonstrates Gamunex improves health-related quality of life in patients with CIDP 3Health News:MMR Announces Webinar to Demonstrate MyMedicalRecords PHR Product Line 2Health News:MMR Announces Webinar to Demonstrate MyMedicalRecords PHR Product Line 3Health News:AAN Foundation Benefits from Grey's Anatomy 'Wedding Registry' 2Health News:Cardinal Rigali Praises House Re-Introduction of 'Pregnant Women Support Act,' Urges Co-Sponsorship 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: